NCT06682429 · University of California, Los Angeles
Telerehabilitation In The Home After Stroke
(TR-2)
What this study is about
The purpose of this research study is to evaluate whether telerehabilitation targeting treatment group$1 movement, when added to usual care, improves treatment group$1 function and reduces global disability after stroke, compared to usual care alone.
View original scientific description
The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone. Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \[1\] TR and usual care; \[2\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age 18-80 years at the time of randomization
- The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±30 days prior to randomization
- The stroke caused upper extremity deficits as defined by Action Research Arm Test score 18-44 (out of 57) at Baseline Visit 1
- Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1
- Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1
- Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)
Exclusion criteria
- A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures
- Unable or unwilling to perform study procedures/therapy, or expectation of noncompliance with study procedures/therapy, or expectation that subject cannot participate in all study visits
- A diagnosis (apart from the index stroke) that substantially affects paretic arm function
- Severe depression, defined as Geriatric Depression Scale Score \>10/15 at Baseline Visit 1
- Significant cognitive impairment, defined as Montreal Cognitive Assessment score \<22 \[a lower score is permitted if due to aphasia and allowed by the site PI\]
- Deficits in communication that interfere with reasonable study participation
- Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis
- Modified Rankin Scale score was \>2 prior to the index stroke
- A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke
- Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye
- Life expectancy \< 9 months
- Pregnant; women of child-bearing potential must have a negative pregnancy test
- Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit
- Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study
- Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions
- Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site \[this can be waived at the discretion of the site PI\]
- Contraindication to MRI
- On isolation precautions, e.g., due to active COVID-19
Where
- Downey, California
- Irvine, California
- Los Angeles, California
- Pomona, California
- San Diego, California
- Washington D.C., District of Columbia
- Jacksonville, Florida
- Miami, Florida
- Atlanta, Georgia
- Kansas City, Kansas
- Boston, Massachusetts
- Charlestown, Massachusetts
And 11 more locations — see the full list below.
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 2, 2026 · Source of record for eligibility and locations